Replies to post #22414 on Cytogenix (fka CYGX)

[Paulness]

CytoGenix Scientists Publish Data Showing the Effectiveness of its Antimicrobial Agent in Animals
Houston, TX, (August 2, 2005) Cytogenix, Inc. (CYGX: OTC: BB)

CytoGenix, Inc. (CYGX: OTC: BB) announces today publication in the August 2005 issue of the American Society of Microbiology journal, Antimicrobial Agents and Chemotherapy of the results of studies conducted by Dr. Xin-Xing Tan, CytoGenix Senior Scientist and Dr. Jeffrey K. Actor, Associate Professor in the department of Pathology and Laboratory Medicine, University of Texas Medical School.

The paper titled "Peptide Nucleic Acid Antisense Oligomer as a Therapeutic Strategy against Bacterial Infection: Proof of Principle Using Mouse Intraperitoneal Infection", demonstrates that one of the company's antimicrobial compounds is highly effective in reducing bacterial load and inflammatory products associated with sepsis in a mouse infection model.

Dr. Malcolm Skolnick, Chairman/CEO commented, "This latest publication from the Company's laboratory represents an important step in our long term plan for the application of our technology in the treatment of infectious diseases. Application of genetic techniques in disease control is the future of medicine and our mission at CytoGenix is to bring this technology from the laboratory to the clinic". Dr. Skolnick adds, "We are encouraged and pleased that our peers in the international medical research community continue to recognize and validate our efforts."